Cellomics Takes High Content Screening to a New Dimension with vHCS™ Virtual High Content Screening
Pittsburgh (May 20, 2002)-Cellomics, Inc. announced today the launch of the new dimension in High Content Screening (HCS) that accelerates “idea to discovery”. Virtual High Content Screening (vHCS), permits our customers to distribute and expand HCS capability throughout the enterprise using any desktop PC to perform virtual HCS on data generated from any instrument anywhere in the organization. Now data, information and new knowledge will be available from anywhere in the organization. Recognizing the need for expanded access to state-of-the-art cell analysis technology, along with the ever-increasing need for connectivity, Cellomics’ vHCS enables global HCS capabilities that are aligned with research and screening workflow patterns. As the pioneer in HCS, Cellomics has extended it’s industry standard platform with a suite of new software tools to satisfy workflow needs in cellular-based discovery.
“vHCS will become the backbone of all High Content Screening programs” stated Dr. Bert Gough, VP of Research and Development. “Our customers will be able to access, visualize, analyze and even perform new virtual assays on existing data from anywhere in the organization from a desktop PC”. “Our vHCS suite of software tools includes vHCS-View that allows visualization of HCS assay results; vHCS-Screen that creates, manages and analyzes assay data, vHCS-Scan that permits re-scanning of existing cellular image data with any biological application, and vHCS-CellSpace that rapidly discovers cellular relationships identified in the scientific literature.” stated Mark Collins, commercial manager for informatics. Cellomics, Inc. is pioneering the field of cellular knowledge extraction. Its’ unique technology, referred to as High Content Screening, integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and informatics tools used to achieve a flexible, broadly applicable platform for users in the life sciences. This automated platform, when applied to lead optimization, predictive toxicology, and new target validation, is proving to reduce the "idea-to-discovery" cycle time in drug discovery, while increasing the probability of the therapeutic success of leads. Currently, Cellomics’ proprietary ArrayScan® HCS Systems are in use at multiple sites within the top ten pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies, and academic centers.
For further information, contact:
Judy P. Masucci, PhD Director, Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412.770.2353 412.770.2450 (fax)
Last Updated ( Monday, 21 June 2004 )
Upcoming Events
December 13, 2008 ASCB 2008 Please visit our booth at the 49th Annual Meeting of the American Society for Cell Biology ...
Home 
Cellomics Takes High Content Screening to a New Dimension with vHCS™ Virtual High Content Screening
top